Guest guest Posted April 3, 2011 Report Share Posted April 3, 2011 HCV Advocate - Top News TopNews EASL 2011 Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment Apr 3 EASL 2011 Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio:FDA Fast Track designations granted for both: the protease inhibitor BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127Apr 2 EASL 2011 PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a Apr 2 EASL 2011 Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients atEASL 2011 Apr 2 EASL 2011 New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response Apr 1 EASL 2011 First Vaccine For Viral Hepatitis C Could Become A Reality Apr 1 EASL 2011 Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders Apr 1 EASL 2011 Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients Apr 1 EASL 2011 Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL Apr 1 FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Group's Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma Mar 31 EASL 2011 OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced rates of depression in HCV patients treated with Locteron Mar 31 EASL 2011 Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination with Pegylated Interferon-Alpha and Ribavirin Mar 31 EASL 2011 Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows Mar 31 Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 Mar 31 Drug Cocktail Offers New Hope for Hepatitis C Patients Mar 31 Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor Mar 30 Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes Mar 30 Achillion Announces Positive RVR Results With ACH-1625 to Treat Chronic Hepatitis C Mar 30 More http://www.hcvadvocate.org/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.